Reaktionsgleichung
[C:1]([O:5][C:6]([N:8]1[CH2:13][CH2:12][CH:11]([CH2:14][O:15][CH2:16][CH:17]([NH2:25])[C:18]2[CH:23]=[CH:22][CH:21]=[CH:20][C:19]=2[F:24])[CH2:10][CH2:9]1)=[O:7])([CH3:4])([CH3:3])[CH3:2].[NH:26]1[C:34]2[C:29](=[CH:30][CH:31]=[C:32]([C:35](O)=[O:36])[CH:33]=2)[CH:28]=[CH:27]1>>[C:1]([O:5][C:6]([N:8]1[CH2:9][CH2:10][CH:11]([CH2:14][O:15][CH2:16][CH:17]([NH:25][C:35]([C:32]2[CH:33]=[C:34]3[C:29]([CH:28]=[CH:27][NH:26]3)=[CH:30][CH:31]=2)=[O:36])[C:18]2[CH:23]=[CH:22][CH:21]=[CH:20][C:19]=2[F:24])[CH2:12][CH2:13]1)=[O:7])([CH3:4])([CH3:2])[CH3:3]Komponenten
3
Versuchsvorschrift
Using coupling method A, 4-[2-amino-2-(2-fluorophenyl)-ethoxymethyl]piperidine-1-carboxylic acid tert-butyl ester (480 mg, 1.4 mmol) and indole-6-carboxylic acid (242 mg, 1.5 mmol) afforded, after purification (SiO2: 0 to 40% 2 N ammonia/methanol solution in DCM), 355 mg (53%) of the title compound.
Aufarbeitung
- customafforded
- customafter purification (SiO2: 0 to 40% 2 N ammonia/methanol solution in DCM), 355 mg (53%) of the title compound
Quellen und Nachweise
- ORD-Eintrag
- ord-414dd79b9a714847a5118d94743e4ad9
- Quelldatensatz
- uspto-grants-2008_09
- Patentnummer
- US07427632B2
Verknüpfte Notizen
Wird geladen…